US · AYTU
Aytu BioPharma, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Englewood, CO 80112
- Website
- aytubio.com
Price · as of 2025-06-30
$2.61
Market cap 20.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $22.90 | +777.39% |
| Intrinsic Value(DCF) | $18.68 | +615.71% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $4,097,561.00 | ||||
| 2012 | $8,195,122.00 | $0.00 | $0.00 | ||
| 2013 | $4,097,561.00 | $2,605,946.90 | $0.00 | $0.00 | $0.00 |
| 2014 | $2,224,390.25 | $1,163,434,319.30 | $6,221,218.90 | $0.00 | $0.00 |
| 2015 | $4,560,000.00 | $3,111,357.60 | $104,786,408,591.03 | $0.00 | $0.00 |
| 2016 | $284,000.00 | $5,046,782.60 | $834,644,569,697.71 | $0.00 | $0.00 |
| 2017 | $15,400.00 | $19,419.16 | $426,375,510.08 | $0.00 | $0.00 |
| 2018 | $750.00 | $3,209.82 | $265,069.32 | $0.00 | $0.00 |
| 2019 | $264.00 | $5,573.33 | $96,073.46 | $0.00 | $0.00 |
| 2020 | $196.00 | $227.58 | $9,807,458.19 | $0.00 | $0.00 |
| 2021 | $65.80 | $188.95 | $42,740,016.46 | $0.00 | $0.00 |
| 2022 | $4.60 | $1.84 | $4,359.32 | $0.00 | $0.00 |
| 2023 | $1.65 | $340.80 | $5,930.31 | $0.00 | $0.00 |
| 2024 | $2.39 | $194.94 | $55.00 | $0.00 | $84.56 |
| 2025 | $2.25 | $22.90 | $25.69 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Aytu BioPharma, Inc.'s (AYTU) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $22.90
- Current price
- $2.61
- AI upside
- +777.39%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$18.68
+615.71% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AYTU | Aytu BioPharma, Inc. | $2.61 | 20.82M | +777% | +616% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| ALUR | Allurion Technologies Inc… | $1.17 | 9.09M | +15,409% | -17% | — | +29,866% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| EKSO | Ekso Bionics Holdings, In… | $10.14 | 24.6M | +55% | -60% | — | +814% | -2.12 | 2.75 | 1.94 | -2.68 | -0.27 | 4.87 | 53.48% | -104.12% | -91.37% | -107.62% | -117.46% | -50.02% | 0.29 | -43.13 | 1.63 | 0.98 | -0.15 | 77679.00% | -2860.00% | 2131.00% | -48.31% | -1.37 | -105.67% | 0.91% | -1.90% | 0.91% | -1.97 | -2.19 | 2.05 | -18.15 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| NVNO | enVVeno Medical Corporati… | $10.00 | 165.03K | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| TXMD | TherapeuticsMD, Inc. | $2.26 | 26.16M | +5,019% | +2,850% | -37% | — | -4.34 | 0.37 | 5.70 | -4.07 | — | 0.44 | 100.00% | -270.30% | -123.85% | -8.16% | -15.04% | -5.63% | 0.26 | -501.05 | 1.92 | 1.67 | -0.71 | -7432.00% | 3525.00% | — | 7.30% | 0.14 | 2.34% | 0.00% | 0.00% | 15.57% | -2.55 | 16.60 | 6.90 | -34.01 |
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
- CEO
- Joshua R. Disbrow
- Employees
- 102
- Beta
- 0.36
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($18.68 ÷ $2.61) − 1 = +615.71% (DCF, example).